Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice

M. A. Ghetie, J. Richardson, T. Tucker, D. Jones, J. W. Uhr, E. S. Vitetta

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

A human Burkitt lymphoma (Daudi) has been grown in the mutant mouse called C.B.-17 SCID. Twenty-eight days after s.c. injection of Daudi cells, a palpable tumor grew only at the site of injection in all injected mice. In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated tumors developed. Following i.v. inoculation, tumors grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic tumor infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the tumors were localized in the abdomen, liver, spleen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow. The growth pattern and phenotype of the Daudi cells were similar whether the inoculated tumor cells were derived from the in vitro cell line or from in vivo passaged tumors. The survival time of the tumor-bearing animals was dependent on the dose of i.v.-administered Daudi cells; as few as 100 cells caused death. All mice injected i.v. showed paresis or paralysis of the hind legs just prior to death. This was associated with the presence of neoplastic nodules within the spinal canal. Two surface antigens on Daudi cells (CD19 and CD22) were stable expressed in all the neoplastic lesions. Radiolabelled anti-CD22 antibodies localized in organs infiltrated with tumor, but did not penetrate primary s.c. tumors. This model of disseminated vs. solid tumor should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti-human B-cell antibodies.

Original languageEnglish (US)
Pages (from-to)481-485
Number of pages5
JournalInternational Journal of Cancer
Volume45
Issue number3
StatePublished - 1990

Fingerprint

B-Lymphocytes
Growth
Neoplasms
Intraperitoneal Injections
Ovary
Spleen
Bone Marrow
Immunoconjugates
Immunotoxins
Lung
Injections
Spinal Canal
Burkitt Lymphoma
Antibodies
Paraplegia
Paresis
Surface Antigens
Intravenous Injections
Abdomen
Femur

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice. / Ghetie, M. A.; Richardson, J.; Tucker, T.; Jones, D.; Uhr, J. W.; Vitetta, E. S.

In: International Journal of Cancer, Vol. 45, No. 3, 1990, p. 481-485.

Research output: Contribution to journalArticle

Ghetie, M. A. ; Richardson, J. ; Tucker, T. ; Jones, D. ; Uhr, J. W. ; Vitetta, E. S. / Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice. In: International Journal of Cancer. 1990 ; Vol. 45, No. 3. pp. 481-485.
@article{c6c6147818a44a6db3e443b87ab9d4a7,
title = "Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice",
abstract = "A human Burkitt lymphoma (Daudi) has been grown in the mutant mouse called C.B.-17 SCID. Twenty-eight days after s.c. injection of Daudi cells, a palpable tumor grew only at the site of injection in all injected mice. In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated tumors developed. Following i.v. inoculation, tumors grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic tumor infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the tumors were localized in the abdomen, liver, spleen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow. The growth pattern and phenotype of the Daudi cells were similar whether the inoculated tumor cells were derived from the in vitro cell line or from in vivo passaged tumors. The survival time of the tumor-bearing animals was dependent on the dose of i.v.-administered Daudi cells; as few as 100 cells caused death. All mice injected i.v. showed paresis or paralysis of the hind legs just prior to death. This was associated with the presence of neoplastic nodules within the spinal canal. Two surface antigens on Daudi cells (CD19 and CD22) were stable expressed in all the neoplastic lesions. Radiolabelled anti-CD22 antibodies localized in organs infiltrated with tumor, but did not penetrate primary s.c. tumors. This model of disseminated vs. solid tumor should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti-human B-cell antibodies.",
author = "Ghetie, {M. A.} and J. Richardson and T. Tucker and D. Jones and Uhr, {J. W.} and Vitetta, {E. S.}",
year = "1990",
language = "English (US)",
volume = "45",
pages = "481--485",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Disseminated or localized growth of a human B-cell tumor (Daudi) in scid mice

AU - Ghetie, M. A.

AU - Richardson, J.

AU - Tucker, T.

AU - Jones, D.

AU - Uhr, J. W.

AU - Vitetta, E. S.

PY - 1990

Y1 - 1990

N2 - A human Burkitt lymphoma (Daudi) has been grown in the mutant mouse called C.B.-17 SCID. Twenty-eight days after s.c. injection of Daudi cells, a palpable tumor grew only at the site of injection in all injected mice. In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated tumors developed. Following i.v. inoculation, tumors grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic tumor infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the tumors were localized in the abdomen, liver, spleen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow. The growth pattern and phenotype of the Daudi cells were similar whether the inoculated tumor cells were derived from the in vitro cell line or from in vivo passaged tumors. The survival time of the tumor-bearing animals was dependent on the dose of i.v.-administered Daudi cells; as few as 100 cells caused death. All mice injected i.v. showed paresis or paralysis of the hind legs just prior to death. This was associated with the presence of neoplastic nodules within the spinal canal. Two surface antigens on Daudi cells (CD19 and CD22) were stable expressed in all the neoplastic lesions. Radiolabelled anti-CD22 antibodies localized in organs infiltrated with tumor, but did not penetrate primary s.c. tumors. This model of disseminated vs. solid tumor should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti-human B-cell antibodies.

AB - A human Burkitt lymphoma (Daudi) has been grown in the mutant mouse called C.B.-17 SCID. Twenty-eight days after s.c. injection of Daudi cells, a palpable tumor grew only at the site of injection in all injected mice. In contrast, after intravenous (i.v.) or intraperitoneal (i.p.) injection, macroscopic, disseminated tumors developed. Following i.v. inoculation, tumors grew in the lungs, kidneys, ovaries and adipose tissue, and microscopic tumor infiltrates were observed in the spleen, bone marrow, spinal column and femur, whereas after i.p. injection, the tumors were localized in the abdomen, liver, spleen, ovaries and muscular tunics of the gut, but did not disseminate into the lung or bone marrow. The growth pattern and phenotype of the Daudi cells were similar whether the inoculated tumor cells were derived from the in vitro cell line or from in vivo passaged tumors. The survival time of the tumor-bearing animals was dependent on the dose of i.v.-administered Daudi cells; as few as 100 cells caused death. All mice injected i.v. showed paresis or paralysis of the hind legs just prior to death. This was associated with the presence of neoplastic nodules within the spinal canal. Two surface antigens on Daudi cells (CD19 and CD22) were stable expressed in all the neoplastic lesions. Radiolabelled anti-CD22 antibodies localized in organs infiltrated with tumor, but did not penetrate primary s.c. tumors. This model of disseminated vs. solid tumor should prove useful for evaluating the efficacy of different types and doses of therapeutic antibodies, immunoconjugates and immunotoxins prepared from anti-human B-cell antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0025261181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025261181&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 481

EP - 485

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -